Kura Oncology reports clinical activity of tipifarnib in subsets of pancreatic cancer
Kura Oncology reported new findings identifying a potential association between CXCL12 expression and clinical benefit in patients with pancreatic cancer treated with tipifarnib. A total of 688 patients were enrolled in study INT-11, of whom 155 reported no abdominal pain at study entry. January 18, 2019